A transgene-free genome editing approach that identifies and replaces mutated resistance genes in metabolic pathways to enhance broad-spectrum fungal disease resistance in high-yielding cultivars of potato, wheat, and barley. Validated in Russet Burbank potato with the StCCoAOMT gene, enabling rapid lignin-based pathogen containment within 72 hours.
This solution offers a genome editing approach to enhance fungal disease resistance in staple crops such as potato, wheat, and barley. Despite decades of conventional breeding, most commercial cultivars lack acceptable resistance to fungal pathogens. The underlying cause is often mutated resistance (R) genes within metabolic pathways that compromise the plant's natural defense response. By combining transcriptomics and metabolomics to identify these mutations, specific gene segments can be replaced with functional versions to restore and strengthen resistance. The approach targets broad-spectrum disease resistance rather than pathogen-specific traits, enabling stacking of multiple edited genes for durable protection.
Key features:
How it works:
The phenylpropanoid pathway produces defense metabolites that are deposited around infection sites to contain pathogens. In susceptible cultivars, key genes such as StCCoAOMT are mutated, breaking this defense. The team uses RNAseq and metabolomics to pinpoint these mutated segments, then employs CRISPR-Cas9 to replace them with functional gene versions. This restores the plant's ability to produce resistance metabolites rapidly upon pathogen attack.
Proof of concept has been demonstrated in Russet Burbank potato, where editing of the StCCoAOMT gene significantly enhanced resistance and contained pathogen spread to a small lesion. The current stage involves extending the transgene-free editing approach to wheat and barley. With industry collaboration and co-funding, the team aims to pursue an NSERC-Alliance grant to scale the approach across additional cultivars. A resistant cultivar is projected within 3-4 years of collaborative development. The technology is at a validation stage transitioning toward broader cultivar application.
McGill University is a comprehensive public research university in Montréal, Québec, known for an international community and a research‑intensive culture. Faculty and industry collaborate through shared core facilities and co‑located labs across downtown and hospital sites, with integration into a major hospital system enabling clinical research and translation. Proximity to Montréal’s established industry clusters and a vibrant innovation district give companies access to talent, pilots, and testbeds. Research is supported by Canada’s Tri‑Agency and the Canada Foundation for Innovation, alongside provincial and philanthropic sources. A dedicated technology transfer office streamlines contracting and IP, supports licensing and sponsored research, and connects partners to startups and entrepreneurship resources.